Developer docs
API playgroundTry for free, no card

Search company profiles

The Cochrane Collaboration

Full company profile

uuid000jvz1

Namestring
The Cochrane Collaboration
Legal namestring
The Cochrane Collaboration
Websiteurl
cochrane.org
Company typeenum
Private
Founded yearint
1992
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
systematic reviews, evidence synthesis, healthcare research, clinical guidelines, evidence-based medicine
Industry2 codes
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code1 code
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Health Evidence Synthesis
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Charitable Grants and Donations
TypeManaged Services
Description

As a registered charity (no. 1045921) in England & Wales, Cochrane is primarily funded through grants, donations, and institutional funding partnerships. The organization operates as a company limited by guarantee (no. 03044323).

cochrane.org
2Publishing and Licensing
TypeSubscription Recurring
Description

Cochrane Library content is published through Wiley, with some resources available open access and others behind subscription access for institutions.

cochrane.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Others
Pricing details1 tier
1Free access to evidence summaries and plain language summaries
ModelFreemiumBilling cadenceOthers
Notes

Cochrane provides free health evidence and learning resources to all. Plain language summaries of evidence are freely accessible.

cochrane.org
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1Cochrane Library
Description

The primary platform for Cochrane's systematic reviews and evidence synthesis content

cochrane.org
+2 more records
Core offering1 text field

The Cochrane Collaboration produces high-quality systematic reviews of healthcare interventions and publishes them through the Cochrane Library, supported by its proprietary Review Manager (RevMan) authoring software, the CENTRAL database of controlled trials, and method-handbooks such as the Cochrane Handbook for Systematic Reviews of Interventions. The organization also offers Cochrane Crowd, Screen4Me, the open-access Cochrane Evidence Synthesis and Methods journal, and the RAISE framework for responsible AI use, serving clinicians, researchers, policymakers, patients, and the public across 100+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Two thirds of new WHO guidelines cite at least 1 Cochrane review in the past 5 years
+1 more record
Product overview1 text field

The Cochrane Collaboration is a global network that produces trusted health evidence through systematic reviews. Its primary product is the Cochrane Library (containing the Cochrane Database of Systematic Reviews and CENTRAL), supported by the Cochrane Handbook for Systematic Reviews of Interventions and Review Manager (RevMan) software. Cochrane offers complementary tools including Cochrane Crowd and Screen4Me for study identification, and recommends third-party tools like Covidence and EPPI-Reviewer for review production. The organization also provides specialized products including the Cochrane Evidence Synthesis and Methods open access journal and the Cochrane Rehabilitation thematic group. Cochrane is actively exploring AI tools for evidence synthesis through initiatives like the CESAR platform study, guided by the RAISE framework for responsible AI use.

Product and service9 records
1Cochrane Library
CategoryEvidence platform / database
Description

An online collection of databases containing high-quality independent evidence to inform healthcare decision-making, including the Cochrane Database of Systematic Reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL). It is the primary platform for accessing Cochrane's systematic reviews, available through both open access content and institutional subscriptions.

2Review Manager (RevMan)
CategoryAuthoring software
Description

Cochrane's proprietary, mandatory, free-to-use software for preparing Cochrane reviews, providing structured text drafting, standard tables, reference formats, meta-analysis capabilities, online help, and error checking, used for editorial submission and publication.

3Cochrane Handbook for Systematic Reviews of Interventions
CategoryMethodological handbook
Description

The official Cochrane Handbook providing comprehensive methodological guidance on conducting systematic reviews of interventions, covering all aspects from planning a review through to completion and updating; current version 6.5.

4Cochrane Central Register of Controlled Trials (CENTRAL)
CategoryEvidence database
Description

A highly concentrated source of reports of randomized and quasi-randomized controlled trials, populated using centralized searches, machine learning technology, and Cochrane Crowd screening, used to populate Cochrane systematic reviews.

5Cochrane Crowd
CategoryCitizen-science screening platform
Description

A crowd-based system that enables volunteers to screen search results to identify randomized trials and other study types, supporting the identification of relevant studies for inclusion in Cochrane reviews.

6Screen4Me
CategoryMachine-learning screening service
Description

A service available to Cochrane review authors that uses machine learning to screen and identify relevant studies for inclusion, particularly for reviews with complex searches and large record sets.

7Cochrane Evidence Synthesis and Methods
CategoryOpen access journal
Description

A fully open access journal that aims to develop the evidence base for how Cochrane produces and publishes evidence syntheses, accepting methods research, scoping reviews, rapid reviews, and evidence gap maps.

8Cochrane Rehabilitation, Functioning, and Disability
CategoryThematic research group
Description

A Cochrane Thematic Group focused on advancing research, refining clinical practices, and enhancing functioning outcomes and quality of life for people with disabling health conditions, supporting evidence production, implementation, and evidence-based practices in rehabilitation worldwide.

9RAISE (Responsible use of AI in evidence SynthEsis) Guidance
CategoryMethodological guidance framework
Description

Cochrane guidance on the responsible use of AI in evidence synthesis, providing recommendations and a responsible handover framework for selecting and using AI tools in systematic reviews.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Cochrane holds official relations status with WHO, providing a stronger platform at the World Health Assembly to advocate for and contribute evidence. Cochrane's CEO participates in WHO events, and WHO guidelines frequently cite Cochrane reviews. This relationship reinforces Cochrane's role in evidence-to-policy systems.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

JBI is a founding partner of World Evidence-based Healthcare Day alongside Cochrane, The Campbell Collaboration, Institute of Development Studies, Centre for Evidence-based Health Care, and Instituto Veredas.

3The Campbell Collaboration
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of World Evidence-based Healthcare Day, partnering with Cochrane and other organizations dedicated to evidence-informed decision-making.

cochrane.org
Strategic tierMinorTypeGTM or Marketing Partner
Description

Cochrane partnered with Devex to host a high-level reception at the World Health Assembly, bringing together global health leaders and funders.

5Wiley
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Cochrane Library content is published through Wiley. International journals publish Cochrane Corners according to agreements between Cochrane Rehabilitation and Wiley.

cochrane.org
6GIN (Guidelines International Network)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Supporting partner of World Evidence-based Healthcare Day 2026 campaign.

cochrane.org
7HTiA (Health Technology Assessment International)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Supporting partner of World Evidence-based Healthcare Day 2026 campaign.

cochrane.org
8The Africa Evidence Youth League
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Supporting partner of World Evidence-based Healthcare Day 2026 campaign focused on youth engagement in evidence-based healthcare.

cochrane.org
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Network of national societies (Association of Academic Physiatrists, Belgian, Catalan, Finnish, French, German, Hellenic, Hungarian, Indonesian, Italian, Netherlands, Romanian, Slovenian, Turkish societies of Physical Medicine and Rehabilitation) involved in education activities, translation, and dissemination of Cochrane content.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Joanna Briggs Institute (JBI)
TypeDirect peer
Description

JBI is the most direct peer to Cochrane — an international evidence-based healthcare research organization producing systematic reviews and implementation resources. JBI is a co-founding partner of World Evidence-based Healthcare Day alongside Cochrane, serves similar clinician/policymaker audiences, and competes in the same evidence-synthesis methodology space.

2Campbell Collaboration
TypeDirect peer
Description

Campbell Collaboration produces systematic reviews of social and economic interventions, mirroring Cochrane's role in health. As a co-founding partner of World Evidence-based Healthcare Day, Campbell competes for the same funder pool and applies overlapping methodological standards, making it a direct peer in the systematic-review infrastructure space.

3Epistemonikos
TypeDirect peer
Description

Epistemonikos is a collaborative, multilingual database of systematic reviews relevant for health decision-making — directly comparable to Cochrane Library as an evidence-aggregation platform. It aggregates reviews from multiple sources (including Cochrane) and serves the same clinician and policymaker audience, making it a direct peer in evidence aggregation.

4PROSPERO (University of York)
TypeDirect peer
Description

PROSPERO is the international prospective register of systematic reviews hosted by the University of York's Centre for Reviews and Dissemination. It is directly comparable to Cochrane's review-protocol infrastructure and serves overlapping researcher audiences planning systematic reviews in health and social care.

5Agency for Healthcare Research and Quality (AHRQ)
TypeBroad incumbent
Description

AHRQ is a US federal agency that funds and produces comparative-effectiveness research and systematic reviews. It is a broad incumbent operating in the same health-evidence space as Cochrane but with a US-government mandate and different funding model, serving overlapping policymaker and clinician audiences.

TypeBroad incumbent
Description

NICE produces health technology assessments and clinical guidelines for the UK NHS, frequently drawing on Cochrane systematic reviews as primary inputs. It is a broad incumbent in evidence-to-policy translation, overlapping with Cochrane on guideline-informing evidence but operating one step downstream in the recommendation pipeline.

7GRADE Working Group
TypeEmerging player
Description

The GRADE Working Group develops the methodology for grading the certainty of evidence and strength of recommendations — used by Cochrane for Summary of Findings tables. It is an emerging/methodological player that defines the standards Cochrane applies, making it a peer at the methodology layer even though it does not produce reviews directly.

TypeOthers
Description

WHO is Cochrane's flagship strategic partner and the largest consumer of Cochrane evidence (two-thirds of new guidelines cite Cochrane reviews). It is included here as a peer/ecosystem participant because it also produces evidence syntheses and guidelines, and its strategic priorities directly shape Cochrane's relevance.

TypeOthers
Description

Wellcome Trust is a major funder of Cochrane (e.g., grant 323143/Z/24/Z supporting the CESAR AI project). It is an ecosystem/financial peer — not a direct competitor — but its funding decisions and broader research-integrity priorities materially shape Cochrane's strategic options.

10Wiley
TypeOthers
Description

Wiley is Cochrane's publishing partner for the Cochrane Library and Cochrane Evidence Synthesis and Methods journal, and coordinates Cochrane Corners distribution through partner journals. Wiley is an ecosystem/partner peer rather than a competitor, but its commercial decisions materially affect Cochrane's distribution and licensing revenue.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Cochrane Collaboration

Health Evidence Synthesiscochrane.org

The Cochrane Collaboration firmographics

Firmographics
Name
The Cochrane Collaboration
Legal name
The Cochrane Collaboration
Website
https://cochrane.org
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

The Cochrane Collaboration industry classification

Industry
Product category
Health Evidence Synthesis
NAICS
Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Systematic reviews
  • Evidence synthesis
  • Healthcare research
  • Clinical guidelines
  • Evidence-based medicine

Where The Cochrane Collaboration is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

The Cochrane Collaboration business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Others

Revenue model

  1. Charitable Grants and Donations: As a registered charity (no. 1045921) in England & Wales, Cochrane is primarily funded through grants, donations, and institutional funding partnerships. The organization operates as a company limited by guarantee (no. 03044323).
  2. Publishing and Licensing: Cochrane Library content is published through Wiley, with some resources available open access and others behind subscription access for institutions.

Pricing tiers

ModelBillingPrice
FreemiumOthersFree access to evidence summaries and plain language summaries

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

The Cochrane Collaboration product offering

Product offering

Core offering

The Cochrane Collaboration produces high-quality systematic reviews of healthcare interventions and publishes them through the Cochrane Library, supported by its proprietary Review Manager (RevMan) authoring software, the CENTRAL database of controlled trials, and method-handbooks such as the Cochrane Handbook for Systematic Reviews of Interventions. The organization also offers Cochrane Crowd, Screen4Me, the open-access Cochrane Evidence Synthesis and Methods journal, and the RAISE framework for responsible AI use, serving clinicians, researchers, policymakers, patients, and the public across 100+ countries.

Product overview

The Cochrane Collaboration is a global network that produces trusted health evidence through systematic reviews. Its primary product is the Cochrane Library (containing the Cochrane Database of Systematic Reviews and CENTRAL), supported by the Cochrane Handbook for Systematic Reviews of Interventions and Review Manager (RevMan) software. Cochrane offers complementary tools including Cochrane Crowd and Screen4Me for study identification, and recommends third-party tools like Covidence and EPPI-Reviewer for review production. The organization also provides specialized products including the Cochrane Evidence Synthesis and Methods open access journal and the Cochrane Rehabilitation thematic group. Cochrane is actively exploring AI tools for evidence synthesis through initiatives like the CESAR platform study, guided by the RAISE framework for responsible AI use.

Differentiator

Problem solved

Functional benefit

Brands

  • Cochrane Library: The primary platform for Cochrane's systematic reviews and evidence synthesis content
  • Cochrane Rehabilitation
  • Cochrane Evidence Synthesis and Methods

Products and services

  • Cochrane Library An online collection of databases containing high-quality independent evidence to inform healthcare decision-making, including the Cochrane Database of Systematic Reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL). It is the primary platform for accessing Cochrane's systematic reviews, available through both open access content and institutional subscriptions.
  • Review Manager (RevMan) Cochrane's proprietary, mandatory, free-to-use software for preparing Cochrane reviews, providing structured text drafting, standard tables, reference formats, meta-analysis capabilities, online help, and error checking, used for editorial submission and publication.
  • Cochrane Handbook for Systematic Reviews of Interventions The official Cochrane Handbook providing comprehensive methodological guidance on conducting systematic reviews of interventions, covering all aspects from planning a review through to completion and updating; current version 6.5.
  • Cochrane Central Register of Controlled Trials (CENTRAL) A highly concentrated source of reports of randomized and quasi-randomized controlled trials, populated using centralized searches, machine learning technology, and Cochrane Crowd screening, used to populate Cochrane systematic reviews.
  • Cochrane Crowd A crowd-based system that enables volunteers to screen search results to identify randomized trials and other study types, supporting the identification of relevant studies for inclusion in Cochrane reviews.
  • Screen4Me A service available to Cochrane review authors that uses machine learning to screen and identify relevant studies for inclusion, particularly for reviews with complex searches and large record sets.
  • Cochrane Evidence Synthesis and Methods A fully open access journal that aims to develop the evidence base for how Cochrane produces and publishes evidence syntheses, accepting methods research, scoping reviews, rapid reviews, and evidence gap maps.
  • Cochrane Rehabilitation, Functioning, and Disability A Cochrane Thematic Group focused on advancing research, refining clinical practices, and enhancing functioning outcomes and quality of life for people with disabling health conditions, supporting evidence production, implementation, and evidence-based practices in rehabilitation worldwide.
  • RAISE (Responsible use of AI in evidence SynthEsis) Guidance Cochrane guidance on the responsible use of AI in evidence synthesis, providing recommendations and a responsible handover framework for selecting and using AI tools in systematic reviews.

Quantifiable outcome

  • Two thirds of new WHO guidelines cite at least 1 Cochrane review in the past 5 years
  • +1 more outcomes

Companies that use The Cochrane Collaboration

Customer profile

Segments4 records

Ideal customer profiles4 records

The Cochrane Collaboration technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

The Cochrane Collaboration partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

  • World Health Organization (WHO)flagshipStrategic or Co-development PartnerCochrane holds official relations status with WHO, providing a stronger platform at the World Health Assembly to advocate for and contribute evidence. Cochrane's CEO participates in WHO events, and WHO guidelines frequently cite Cochrane reviews. This relationship reinforces Cochrane's role in evidence-to-policy systems.
  • JBI (Joanna Briggs Institute)coreStrategic or Co-development PartnerJBI is a founding partner of World Evidence-based Healthcare Day alongside Cochrane, The Campbell Collaboration, Institute of Development Studies, Centre for Evidence-based Health Care, and Instituto Veredas.
  • The Campbell CollaborationcoreStrategic or Co-development PartnerCo-founder of World Evidence-based Healthcare Day, partnering with Cochrane and other organizations dedicated to evidence-informed decision-making.
  • DevexminorGTM or Marketing PartnerCochrane partnered with Devex to host a high-level reception at the World Health Assembly, bringing together global health leaders and funders.
  • WileycoreImplementation/ SI/ Consulting PartnerCochrane Library content is published through Wiley. International journals publish Cochrane Corners according to agreements between Cochrane Rehabilitation and Wiley.
  • GIN (Guidelines International Network)minorStrategic or Co-development PartnerSupporting partner of World Evidence-based Healthcare Day 2026 campaign.
  • HTiA (Health Technology Assessment International)minorStrategic or Co-development PartnerSupporting partner of World Evidence-based Healthcare Day 2026 campaign.
  • The Africa Evidence Youth LeagueminorStrategic or Co-development PartnerSupporting partner of World Evidence-based Healthcare Day 2026 campaign focused on youth engagement in evidence-based healthcare.
  • Cochrane Rehabilitation Partner National SocietiescoreChannel Partner/ Reseller/ DistributorNetwork of national societies (Association of Academic Physiatrists, Belgian, Catalan, Finnish, French, German, Hellenic, Hungarian, Indonesian, Italian, Netherlands, Romanian, Slovenian, Turkish societies of Physical Medicine and Rehabilitation) involved in education activities, translation, and dissemination of Cochrane content.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

The Cochrane Collaboration competitors and assessment

Company assessment

Direct peers

  • Joanna Briggs Institute (JBI): JBI is the most direct peer to Cochrane — an international evidence-based healthcare research organization producing systematic reviews and implementation resources. JBI is a co-founding partner of World Evidence-based Healthcare Day alongside Cochrane, serves similar clinician/policymaker audiences, and competes in the same evidence-synthesis methodology space.
  • Campbell Collaboration: Campbell Collaboration produces systematic reviews of social and economic interventions, mirroring Cochrane's role in health. As a co-founding partner of World Evidence-based Healthcare Day, Campbell competes for the same funder pool and applies overlapping methodological standards, making it a direct peer in the systematic-review infrastructure space.
  • Epistemonikos: Epistemonikos is a collaborative, multilingual database of systematic reviews relevant for health decision-making — directly comparable to Cochrane Library as an evidence-aggregation platform. It aggregates reviews from multiple sources (including Cochrane) and serves the same clinician and policymaker audience, making it a direct peer in evidence aggregation.
  • PROSPERO (University of York): PROSPERO is the international prospective register of systematic reviews hosted by the University of York's Centre for Reviews and Dissemination. It is directly comparable to Cochrane's review-protocol infrastructure and serves overlapping researcher audiences planning systematic reviews in health and social care.

Broad incumbents

  • Agency for Healthcare Research and Quality (AHRQ): AHRQ is a US federal agency that funds and produces comparative-effectiveness research and systematic reviews. It is a broad incumbent operating in the same health-evidence space as Cochrane but with a US-government mandate and different funding model, serving overlapping policymaker and clinician audiences.
  • National Institute for Health and Care Excellence (NICE): NICE produces health technology assessments and clinical guidelines for the UK NHS, frequently drawing on Cochrane systematic reviews as primary inputs. It is a broad incumbent in evidence-to-policy translation, overlapping with Cochrane on guideline-informing evidence but operating one step downstream in the recommendation pipeline.

Emerging players

  • GRADE Working Group: The GRADE Working Group develops the methodology for grading the certainty of evidence and strength of recommendations — used by Cochrane for Summary of Findings tables. It is an emerging/methodological player that defines the standards Cochrane applies, making it a peer at the methodology layer even though it does not produce reviews directly.

Others

  • World Health Organization (WHO): WHO is Cochrane's flagship strategic partner and the largest consumer of Cochrane evidence (two-thirds of new guidelines cite Cochrane reviews). It is included here as a peer/ecosystem participant because it also produces evidence syntheses and guidelines, and its strategic priorities directly shape Cochrane's relevance.
  • Wellcome Trust: Wellcome Trust is a major funder of Cochrane (e.g., grant 323143/Z/24/Z supporting the CESAR AI project). It is an ecosystem/financial peer — not a direct competitor — but its funding decisions and broader research-integrity priorities materially shape Cochrane's strategic options.
  • Wiley: Wiley is Cochrane's publishing partner for the Cochrane Library and Cochrane Evidence Synthesis and Methods journal, and coordinates Cochrane Corners distribution through partner journals. Wiley is an ecosystem/partner peer rather than a competitor, but its commercial decisions materially affect Cochrane's distribution and licensing revenue.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

The Cochrane Collaboration social profiles

Digital presence

The Cochrane Collaboration financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Cochrane Collaboration leadership team

Management profile

Number of profiles

Profiles6 records

The Cochrane Collaboration funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Cochrane Collaboration M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Cochrane Collaboration

What does The Cochrane Collaboration do?

The Cochrane Collaboration produces high-quality systematic reviews of healthcare interventions and publishes them through the Cochrane Library, supported by its proprietary Review Manager (RevMan) authoring software, the CENTRAL database of controlled trials, and method-handbooks such as the Cochrane Handbook for Systematic Reviews of Interventions. The organization also offers Cochrane Crowd, Screen4Me, the open-access Cochrane Evidence Synthesis and Methods journal, and the RAISE framework for responsible AI use, serving clinicians, researchers, policymakers, patients, and the public across 100+ countries.

Is The Cochrane Collaboration a public or private company?

The Cochrane Collaboration is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was The Cochrane Collaboration founded?

The Cochrane Collaboration was founded in 1992. It employs 1 to 10 people.

Where is The Cochrane Collaboration based?

The Cochrane Collaboration is headquartered in London, United Kingdom, in the Europe region.

How does The Cochrane Collaboration make money?

Two revenue lines are on record. Charitable Grants and Donations are the primary driver. The others are publishing and Licensing.

Who are The Cochrane Collaboration's main competitors?

Direct peers on record are Joanna Briggs Institute (JBI), Campbell Collaboration, Epistemonikos and PROSPERO (University of York). Broad incumbents are Agency for Healthcare Research and Quality (AHRQ) and National Institute for Health and Care Excellence (NICE). GRADE Working Group is listed as an emerging player. Others are World Health Organization (WHO), Wellcome Trust and Wiley.

Does The Cochrane Collaboration have an API?

No public API is recorded for The Cochrane Collaboration.

What industry is The Cochrane Collaboration in?

The Cochrane Collaboration's product category is Health Evidence Synthesis. Its primary akta.pro industry code is HLAJAKAN, Global Health Research, Evidence & Technical Assistance Organizations, with a secondary code of HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms. Its NAICS code is 541690 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalCochrane review challenges benefits of turmeric supplements for knee osteoarthritisA Cochrane review of 9 studies involving 1,245 people with knee osteoarthritis found turmeric supplements provided little or no clinically important pain relief compared to placebo or NSAIDs. The review applied formal trustworthiness screening, which excluded 10 trials with unresolved concerns, leading to more cautious conclusions than earlier reviews.The IndependentPopular supplement found to offer little benefit to osteoarthritis patientsA Cochrane review of nine studies on 1,245 people with knee osteoarthritis found turmeric supplements offered no pain relief compared to placebo or standard anti-inflammatory drugs. The review noted some studies were limited and evidence remains uncertain, leading the lead author to advise against routine recommendation.ScienmagCochrane Review Finds Turmeric Supplements Offer Little Relief for KneeA Cochrane systematic review of nine trials found turmeric supplements offer little or no clinically important pain relief for knee osteoarthritis. The review, including 1,245 participants, compared turmeric to placebos and standard medications, concluding no clear benefit. Lead author Dr. Ivan Shirinsky said he would not routinely recommend them.SciTechDailyA Study of 50,000 Children Reveals the Real Impact of Daily Iron PillsA Cochrane review of 114 studies involving over 50,000 children found daily iron supplements reduce iron deficiency anemia but do not improve growth or protect against common illnesses. The review, led by Cornell researchers, notes limited evidence for combined supplements and cautions against universal use.MedicalxpressNew evidence questions benefits of turmeric for knee arthritisA Cochrane review of nine studies involving 1,245 people with knee osteoarthritis found turmeric supplements provided little or no clinically important pain relief. The review, which applied formal trustworthiness screening, concluded that turmeric was not more effective than placebo or NSAIDs, and the lead author would not routinely recommend it.The IndependentNew study challenges the ‘health benefits’ of turmeric supplementsA Cochrane review of nine studies on turmeric supplements for knee osteoarthritis found no benefit over placebo or NSAIDs. The review included 1,245 participants aged 52-62, with trials lasting four weeks to three months. Lead author Dr Ivan Shirinsky said he would not routinely recommend turmeric supplements.ExameJejum intermitente funciona? O que a ciência diz sobre emagrecimento, glicemia e longevidadeA Cochrane review published in February 2026 found that intermittent fasting does not show superior weight loss compared to conventional diets. Evidence for other benefits like blood sugar control, cardiovascular health, and longevity remains limited or inconclusive. The review recommends medical evaluation before adopting such practices.News-MedicalDaily iron supplements reduce anemia risk in children without increasing common illnessesA Cochrane review of 114 studies with over 50,000 children found daily iron supplements reduce iron deficiency anemia risk with little effect on common illnesses. The review supports continued use where iron deficiency is a concern, but notes side effects like stool discoloration and uncertain evidence for vomiting and constipation.News-MedicalKangaroo care reduces newborn mortality and serious hospital infectionsA Cochrane review of 49 randomized trials involving 7,724 low birthweight or preterm newborns found kangaroo care likely reduces hospital deaths and serious infections, especially in low-resource settings. The review doubled the number of studies from the 2016 version, strengthening evidence for the practice.Nate미숙아 생존율 높이는 '캥거루 케어'…사망·중증 감염 위험 감소 : 네이트 뉴스A Cochrane review of 49 randomized trials found Kangaroo Mother Care reduces mortality and severe infection risk in premature and low-birth-weight infants. The analysis included 7,724 infants, more than double the 2016 review, and showed benefits especially in low-resource settings. The WHO recommends at least 8 hours daily, but optimal duration remains unclear.